# Elvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 Diabetes - businesswire.com

*Источник: businesswire.com*
*Дата: 2026-09-15*
*Язык: en*

<a href="https://news.google.com/rss/articles/CBMijAJBVV95cUxOanJmb3FWY05qdGwxVlZINWtDS3Z6QmVDVkZkV0VaUHBpTUJudHZFLUJWV2Q1ejJlWm1BM2pOU2dhTzVzcEMzWTlRVE9UMDBHc1dMTWRQTzY5Zk9UZXZkSkFvWkxITmJzUUFucjN0VWVKUWpoSkVXZ0JibWJsWjlyakdoZGxDN25HbjdGLVQxc3c3c1Z4bUkxNUtEZHBVOGdkaGNya1BsZTkwZjlnT2hBRGE4SGx5b253d19LZ0tGZzBQMWFTNGY3NnN3MzVwUVJWdVJwSm5RUXlDZDMzM3paeWZUOVNxZ3JTTWRhTlZSOGZhWHR2ODAyeVh5Znl1VDFfTlFkc0N1LW5TSWN0?oc=5" target="_blank">Elvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 Diabetes</a>&nbsp;&nbsp;<font color="#6f6f6f">businesswire.com</font>

[Оригинал](https://www.businesswire.com/news/home/20260915187568/en/Elvinix-Secures-Exclusive-License-to-Advance-Novel-Peptide-Therapy-Aimed-at-Restoring-Insulin-Production-in-Type-1-Diabetes)